Home › Laryngeal Cancer › Illinois › Springfield
Laryngeal Cancer clinical trials in Springfield, IL
3 studies for Laryngeal Cancer are looking for participants at sites in and around Springfield (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- Southern Illinois University School of Medicine, Springfield
- Springfield Clinic, Springfield
- Springfield Memorial Hospital, Springfield
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Southern Illinois University School of Medicine, Springfield
- Springfield Clinic, Springfield
- Springfield Memorial Hospital, Springfield
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Southern Illinois University School of Medicine, Springfield
- Springfield Clinic, Springfield
- Springfield Memorial Hospital, Springfield
Laryngeal Cancer trials in other cities
- Chicago, IL8 studies
- Milwaukee, WI8 studies
- Atlanta, GA8 studies
- Kansas City, MO7 studies
- St. Louis, MO7 studies
- Baltimore, MD6 studies
- Edison, NJ6 studies
- Cincinnati, OH6 studies
- Richmond, VA6 studies
- Pittsburgh, PA6 studies
- Durham, NC6 studies
- Portland, OR6 studies
Other studies in Springfield
- Non-Small Cell Lung Cancer13 studies
- Lung Cancer12 studies
- Colorectal Cancer9 studies
- Breast Cancer8 studies
- Acute Myeloid Leukemia8 studies
- Cancer (all types)7 studies
- Prostate Cancer6 studies
- Kidney Cancer (Renal Cell Carcinoma)6 studies
- Bladder Cancer6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Pancreatic Cancer5 studies
- Melanoma5 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.